Management of Genital HPV Infection in HIV-Positive Men
HIV-positive men with genital HPV should receive the same treatment for visible warts as HIV-negative men, but require heightened vigilance for treatment failure, more frequent recurrences, and increased risk of malignancy. 1
Treatment Goals and Expectations
The primary objective is removal of visible, symptomatic warts—not eradication of HPV infection. 1 Current therapies do not eliminate the virus or demonstrably reduce transmission risk to partners. 1 Treatment induces wart-free periods but does not cure the underlying infection. 1
Natural History Considerations
- 20–30% of untreated genital warts resolve spontaneously within 3 months, making observation acceptable for asymptomatic patients. 1
- Recurrence occurs in approximately 30% of cases regardless of treatment modality, typically from reactivation of subclinical infection rather than reinfection. 1
- Most warts respond within 3 months of therapy; lack of response warrants escalation. 1
First-Line Treatment Options
Provider-Administered Therapies
- Cryotherapy with liquid nitrogen is the preferred office-based option, repeated every 1–2 weeks until clearance, achieving 63–88% cure rates with 21–39% recurrence. 1
- Trichloroacetic acid (TCA) 80–90% applied weekly to warts yields ≈81% efficacy with ≈36% recurrence; powder with talc or sodium bicarbonate to remove unreacted acid. 1
- Podophyllin resin 10–25% can be applied weekly and washed off after 1–4 hours. 1
Patient-Applied Therapies
- Podofilox 0.5% solution applied twice daily for 3 days, followed by 4 days off therapy, repeated for up to 4 cycles. 1
- Imiquimod 5% cream applied 3 times weekly for up to 16 weeks until warts clear or maximum treatment period reached. 1
- Imiquimod 3.75% cream is a newer formulation available for AGW treatment. 2
Location-Specific Considerations
Warts on moist or intertriginous surfaces respond better to topical agents (TCA, podophyllin, podofilox, imiquimod) than to ablative methods. 1
When to Escalate or Change Therapy
Switch to a different modality when there is no substantial improvement after:
- 3 provider-administered treatments, OR
- 6 total treatments of any type, OR
- 8 weeks of patient-applied therapy. 1
Advanced/Surgical Options for Refractory Disease
- Electrosurgery/electrodesiccation destroys warts under local anesthesia without requiring additional hemostasis. 1
- Carbon dioxide laser ablation is reserved for extensive or treatment-resistant disease. 1
- Surgical excision can be used for refractory lesions. 1
Special Considerations for HIV-Positive Men
Treatment Response and Complications
HIV-infected individuals may have larger or more numerous warts and may not respond as well to therapy, experiencing more frequent recurrences. 1 The immune dysfunction induced by HIV impairs HPV clearance and increases oncogenic risk. 3
Malignancy Risk
HIV-positive men are at higher risk for squamous cell carcinomas arising in or resembling genital warts. 1 High-risk HPV types (16,18,31,33,35) are occasionally found in visible genital warts and are strongly associated with external genital squamous intraepithelial neoplasia. 2
When to Biopsy
Reserve biopsy for:
- Uncertain diagnosis
- Treatment failure or disease worsening during therapy
- Immunocompromised patients (including HIV-positive men)
- Lesions that are pigmented, indurated, fixed, or ulcerated. 1
Routine biopsy of typical genital warts is not recommended. 1
Anal Cancer Screening
Data are insufficient to recommend routine anal cancer screening with anal cytology in HIV-positive men or MSM. 2 However, an annual digital anorectal examination (DARE) may be useful for early detection of anal masses in HIV-positive men and MSM with a history of receptive anal intercourse. 2
The incidence of anal cancer is substantially higher among HIV-positive MSM (80–131 cases per 100,000 person-years) compared to the general population (1–2 cases per 100,000 person-years). 2 Despite effective antiretroviral therapy, the burden of HPV-related anal disease remains a significant concern in the aging HIV population. 3
HPV Vaccination
The quadrivalent HPV vaccine (Gardasil) is recommended for HIV-positive males aged 9–26 years, regardless of prior HPV infection or existing warts. 1 The vaccine prevents infection with HPV types 6 and 11, which cause ≈90% of genital warts, and types 16 and 18, which cause ≈70% of cervical cancers. 1
- Vaccination does not treat existing warts but reduces the risk of acquiring new vaccine-covered HPV types. 1
- The vaccine is safe and immunogenic in HIV-positive populations. 4
- Increased immunogenicity has been reported in persons on antiretroviral therapy compared with antiretroviral-naïve persons. 4
Patient Counseling
Transmission and Partner Management
- Treating visible warts does not eliminate HPV infection nor demonstrably lower transmission risk to partners. 1
- Consistent condom use may reduce but not eliminate HPV transmission because the virus can infect uncovered genital skin. 1
- HPV diagnosis does not necessarily indicate sexual infidelity; the virus is highly prevalent and many partners are already infected. 1
Prognosis and Expectations
- No evidence links wart treatment to a reduction in cervical cancer risk among female partners. 1
- Most recurrences result from reactivation of subclinical infection rather than reinfection by a partner. 1
Common Pitfalls and Safety Considerations
Overtreatment with ablative methods can cause persistent hypo- or hyperpigmentation and may lead to depressed or hypertrophic scarring; adequate healing intervals between sessions are essential. 1
Appropriate infection control is recommended when performing laser or electrocautery, including performing procedures in ventilated rooms using standard precautions, to prevent possible transmission to healthcare workers. 2
HIV-positive men require more aggressive surveillance for treatment failure and malignant transformation given their impaired immune response and higher risk of HPV-associated cancers. 1, 3